AirSculpt Technologies Reports Second Quarter Fiscal 2025 Results
AirSculpt Technologies (NASDAQ:AIRS), a premium body contouring provider, reported Q2 2025 results showing revenue decline of 13.7% to $44.0 million compared to Q2 2024. The company posted a net loss of $0.6 million, improved from a $3.2 million loss in Q2 2024. Case volume decreased by 14.1% to 3,392 cases.
The company announced two strategic initiatives: a pilot program for skin tightening services targeting GLP-1 users, and expanded financing options. Additionally, AirSculpt reduced its debt by $16 million following a successful common stock offering in June 2025.
The company maintained its full-year 2025 guidance of $160-170 million in revenue and $16-18 million in Adjusted EBITDA. CFO Dennis Dean announced his retirement but will remain until a successor is appointed.
AirSculpt Technologies (NASDAQ:AIRS), un fornitore premium di body contouring, ha riportato i risultati del secondo trimestre 2025 con un calo dei ricavi del 13,7% a 44,0 milioni di dollari rispetto al secondo trimestre 2024. L'azienda ha registrato una perdita netta di 0,6 milioni di dollari, migliorata rispetto alla perdita di 3,2 milioni nel Q2 2024. Il volume dei casi è diminuito del 14,1% a 3.392 casi.
L'azienda ha annunciato due iniziative strategiche: un programma pilota per servizi di rassodamento della pelle rivolto agli utenti di GLP-1 e l'ampliamento delle opzioni di finanziamento. Inoltre, AirSculpt ha ridotto il proprio debito di 16 milioni di dollari a seguito di un'offerta di azioni ordinarie andata a buon fine nel giugno 2025.
L'azienda ha confermato la guidance per l'intero anno 2025, prevedendo ricavi tra 160 e 170 milioni di dollari e un EBITDA rettificato tra 16 e 18 milioni di dollari. Il CFO Dennis Dean ha annunciato il suo pensionamento, ma resterà in carica fino alla nomina del successore.
AirSculpt Technologies (NASDAQ:AIRS), un proveedor premium de contorno corporal, reportó resultados del segundo trimestre de 2025 mostrando una disminución de ingresos del 13,7% hasta 44,0 millones de dólares en comparación con el segundo trimestre de 2024. La compañía registró una pérdida neta de 0,6 millones de dólares, mejorando desde una pérdida de 3,2 millones en el Q2 de 2024. El volumen de casos disminuyó un 14,1% hasta 3,392 casos.
La empresa anunció dos iniciativas estratégicas: un programa piloto para servicios de reafirmación de la piel dirigido a usuarios de GLP-1 y la ampliación de opciones de financiamiento. Además, AirSculpt redujo su deuda en 16 millones de dólares tras una exitosa oferta de acciones ordinarias en junio de 2025.
La compañía mantuvo su guía para todo el año 2025 con ingresos de 160-170 millones de dólares y EBITDA ajustado de 16-18 millones de dólares. El CFO Dennis Dean anunció su retiro pero permanecerá hasta que se nombre un sucesor.
AirSculpt Technologies (NASDAQ:AIRS)는 프리미엄 바디 컨투어링 제공업체로, 2025년 2분기 실적에서 2024년 2분기 대비 13.7% 감소한 4,400만 달러의 매출을 보고했습니다. 회사는 60만 달러의 순손실을 기록했으나, 이는 2024년 2분기 320만 달러 손실에서 개선된 수치입니다. 시술 건수는 14.1% 감소한 3,392건이었습니다.
회사는 GLP-1 사용자 대상 피부 탄력 강화 서비스 파일럿 프로그램과 금융 옵션 확대라는 두 가지 전략적 이니셔티브를 발표했습니다. 또한, 2025년 6월 성공적인 보통주 공모를 통해 1,600만 달러의 부채를 감축했습니다.
회사는 2025년 연간 매출을 1억 6,000만~1억 7,000만 달러, 조정 EBITDA를 1,600만~1,800만 달러로 유지할 것이라고 밝혔습니다. CFO 데니스 딘은 은퇴를 발표했으나 후임자가 임명될 때까지 자리를 유지할 예정입니다.
AirSculpt Technologies (NASDAQ:AIRS), un fournisseur premium de remodelage corporel, a publié ses résultats du deuxième trimestre 2025 montrant une baisse de chiffre d'affaires de 13,7 % à 44,0 millions de dollars par rapport au deuxième trimestre 2024. La société a enregistré une perte nette de 0,6 million de dollars, améliorée par rapport à une perte de 3,2 millions au T2 2024. Le volume des cas a diminué de 14,1 % à 3 392 cas.
L'entreprise a annoncé deux initiatives stratégiques : un programme pilote pour des services de raffermissement de la peau ciblant les utilisateurs de GLP-1, ainsi qu'une extension des options de financement. De plus, AirSculpt a réduit sa dette de 16 millions de dollars suite à une émission d'actions ordinaires réussie en juin 2025.
La société a maintenu ses prévisions pour l'ensemble de l'année 2025, avec un chiffre d'affaires attendu entre 160 et 170 millions de dollars et un EBITDA ajusté entre 16 et 18 millions de dollars. Le directeur financier Dennis Dean a annoncé sa retraite mais restera en poste jusqu'à la nomination de son successeur.
AirSculpt Technologies (NASDAQ:AIRS), ein Premium-Anbieter für Körperkonturierung, meldete für das zweite Quartal 2025 einen Umsatzrückgang von 13,7 % auf 44,0 Millionen US-Dollar im Vergleich zum zweiten Quartal 2024. Das Unternehmen verzeichnete einen Nettoverlust von 0,6 Millionen US-Dollar, was eine Verbesserung gegenüber dem Verlust von 3,2 Millionen im Q2 2024 darstellt. Das Fallvolumen sank um 14,1 % auf 3.392 Fälle.
Das Unternehmen kündigte zwei strategische Initiativen an: ein Pilotprogramm für Hautstraffungsdienste, das sich an GLP-1-Nutzer richtet, sowie erweiterte Finanzierungsmöglichkeiten. Zudem reduzierte AirSculpt seine Schulden um 16 Millionen US-Dollar nach einem erfolgreichen Aktienangebot im Juni 2025.
Das Unternehmen bestätigte seine Prognose für das Gesamtjahr 2025 mit einem Umsatz zwischen 160 und 170 Millionen US-Dollar und einem bereinigten EBITDA von 16 bis 18 Millionen US-Dollar. CFO Dennis Dean gab seinen Rücktritt bekannt, bleibt aber bis zur Ernennung eines Nachfolgers im Amt.
- Net loss improved to $0.6M from $3.2M in Q2 2024
- Debt reduction of $16M following successful stock offering
- Record growth in leads and increased consultations
- Launch of new skin tightening service targeting GLP-1 users
- Maintained full-year guidance despite challenges
- Revenue declined 13.7% year-over-year to $44M
- Case volume dropped 14.1% to 3,392 cases
- Adjusted EBITDA decreased to $5.8M from $6.9M year-over-year
- CFO retirement announcement creates leadership transition uncertainty
Insights
AirSculpt reports continued revenue decline but shows improvement trajectory with narrowing losses and strategic initiatives amid market challenges.
AirSculpt Technologies delivered mixed Q2 2025 results, with revenue declining
The company substantially narrowed its net loss to
Management's strategic initiatives are showing early promise, with record lead generation and increased consultations pointing to growing consumer interest. The company has begun piloting two notable new offerings: skin tightening services (strategically targeting patients using GLP-1 weight loss medications) and expanded financing options to improve affordability.
The balance sheet strengthened considerably with a
The announced CFO transition creates some uncertainty, though the planned overlap period should mitigate disruption risk. Management maintained its full-year guidance of
While not explicitly stated, the results suggest AirSculpt may be experiencing market headwinds from macroeconomic pressures affecting elective procedures and possibly competition from GLP-1 weight loss medications, which they're now strategically adapting to with new service offerings.
MIAMI BEACH, Fla., Aug. 01, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the “Company”), a national provider of premium body contouring procedures, today announced results for the second quarter ended June 30, 2025. The Company also announced that Dennis Dean intends to retire from his position of Chief Financial Officer. Mr. Dean will retain his role until a permanent successor is in place.
Yogi Jashnani, Chief Executive Officer, stated: “In an ongoing dynamic environment, the second quarter saw us advance our transformation initiatives, and based on our results and our outlook, we remain on track to achieve our annual guidance. We narrowed our year-over-year revenue decline by four percentage points versus the first quarter; grew leads by a record level; and delivered a meaningful increase in consultations. All of this demonstrates the increasing consumer interest in and strength of AirSculpt.”
“In the quarter, we began to pilot two new offerings - skin tightening, a core competency of ours that capitalizes on the skin laxity associated with the use of GLP-1’s - and an expansion in our financing options to provide greater flexibility for consumers. These are examples of our enhanced growth strategy and, alongside our elevated go-to market processes, increase our confidence in our ability to accelerate our comparable sales improvement throughout the year. Importantly, we have strengthened our balance sheet with the reduction of our debt by
Second Quarter 2025 Results
- Case volume was 3,392 for the second quarter of 2025, representing a
14.1% decline from the fiscal year 2024 second quarter case volume of 3,949; - Revenue declined
13.7% to$44.0 million from$51.0 million in the fiscal year 2024 second quarter; - Net loss for the quarter was
$0.6 million compared to net loss of$3.2 million in the fiscal year 2024 second quarter; and - Adjusted EBITDA was
$5.8 million compared to$6.9 million for the fiscal year 2024 second quarter.
First Six Months 2025 Results
- Case volume was 6,468, a decline of
15.9% from the first six months of fiscal year 2024 case volume of 7,695; - Revenue declined
15.5% to$83.4 million from$98.6 million in the first six months of fiscal year 2024; - Net loss was
$3.4 million compared to net income of$2.8 million in the first six months of fiscal year 2024; and - Adjusted EBITDA was
$9.6 million compared to$14.2 million for the first six months of fiscal year 2024.
2025 Outlook
The Company is affirming its full year 2025 revenue and adjusted EBITDA guidance as follows:
- Revenues of approximately
$160 t o$170 million - Adjusted EBITDA of approximately
$16 t o$18 million
For additional information on forward-looking statements, see the section titled "Forward-Looking Statements" below.
Liquidity
As of June 30, 2025, the Company had
Subsequent Event
The Company announced today that Dennis Dean intends to retire from his position of Chief Financial Officer. Mr. Dean will retain his role until a permanent successor is in place.
Commenting on the announcement, Mr. Jashnani noted: “Dennis has been integral to our business having implemented the financial framework and built and led the organization that supported our successful initial public offering, and most recently our common stock offering.”
Dennis Dean stated: “We have a strong financial team, an improved capital structure and a strategy in place to allow the Company to return to consistent profitable growth. I am committed to remaining at AirSculpt to ensure a seamless transition of my responsibilities once a new CFO is in place.”
Conference Call Information
AirSculpt will hold a conference call today, August 1, 2025 at 8:30 am (Eastern Time). The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13753206 or by visiting the link below to request a return call for instant telephone access to the event.
https://callme.viavid.com/viavid/?callme=true&passcode=13725116&h=true&info=company&r=true&B=6
The live webcast may be accessed via the investor relations section of the AirSculpt Technologies website at https://investors.airsculpt.com. A replay of the webcast will be available for approximately 90 days following the call.
To learn more about AirSculpt, please visit the Company's website at https://investors.airsculpt.com. AirSculpt uses its website as a channel of distribution for material Company information. Financial and other material information regarding AirSculpt is routinely posted on the Company's website and is readily accessible.
About AirSculpt
AirSculpt is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin, while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results.
Forward-Looking Statements
This press release contains forward-looking statements. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” the negative of these terms and other comparable terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements, which are subject to risks, uncertainties, and assumptions about us, may include projections of our future financial performance, our anticipated growth strategies, and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. You are cautioned that there are important risks and uncertainties, many of which are beyond our control, that could cause our actual results, level of activity, performance, or achievements to differ materially from the projected results, level of activity, performance or achievements that are expressed or implied by such forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements, including those factors discussed in the section titled “Risk Factors” in our Annual Report on Form 10-K.
Our future results could be affected by a variety of other factors, including, but not limited to, inability to sell equity or other securities in the future at a time when we might otherwise wish to effect sales; inability to raise capital on commercially reasonable terms, if at all; the risk that any future financings may dilute our stockholders or restrict our business; failure to stabilize same-store performance; not being able to optimize our marketing investment, go-to-market strategy and sales process; not having the ability to expand our financing options for consumers; being unsuccessful in further product innovations; failure to operate centers in a cost-effective manner; increased operating expenses due to rising inflation; increased competition in the weight loss and obesity solutions market, including as a result of the recent regulatory approval, increased market acceptance, availability and customer awareness of weight-loss drugs; shortages or quality control issues with third-party manufacturers or suppliers; competition for surgeons; litigation or medical malpractice claims; inability to protect the confidentiality of our proprietary information; changes in the laws governing the corporate practice of medicine or fee-splitting; changes in the regulatory, macroeconomic conditions, including inflation and the threat of recession, economic and other conditions of the states and jurisdictions where our facilities are located; and business disruption or other losses from natural disasters, war, pandemic, terrorist acts or political unrest.
The risk factors discussed in “Item 1A. Risk Factors” in our Annual Report on Form 10-K and in other filings we make from time to time with the SEC could cause our results to differ materially from those expressed in the forward-looking statements made in this press release.
There also may be other risks and uncertainties that are currently unknown to us or that we are unable to predict at this time.
Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. Forward-looking statements represent our estimates and assumptions only as of the date they were made, which are inherently subject to change, and we are under no duty and we assume no obligation to update any of these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated after the date of this press release to conform our prior statements to actual results or revised expectations, except as required by law. Given these uncertainties, investors should not place undue reliance on these forward-looking statements.
Use of Non-GAAP Financial Measures
The Company reports financial results in accordance with generally accepted accounting principles in the United States (“GAAP”), however, the Company believes the evaluation of ongoing operating results may be enhanced by a presentation of Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income and Adjusted Net Income per Share, which are non-GAAP financial measures. Although the Company provides guidance for Adjusted EBITDA, it is not able to provide guidance for net income, the most directly comparable GAAP measure. Certain elements of the composition of net income, including equity-based compensation, are not predictable, making it impractical for us to provide guidance on net income or to reconcile our Adjusted EBITDA guidance to net income without unreasonable efforts. For the same reasons, the Company is unable to address the probable significance of the unavailable information regarding net income, which could be material to future results.
These non-GAAP financial measures are not intended to replace financial performance measures determined in accordance with GAAP. Rather, they are presented as supplemental measures of the Company's performance that management believes may enhance the evaluation of the Company's ongoing operating results. These non-GAAP financial measures are not presented in accordance with GAAP, and the Company’s computation of these non-GAAP financial measures may vary from similar measures used by other companies. These measures have limitations as an analytical tool and should not be considered in isolation or as a substitute or alternative to revenue, net income, operating income, cash flows from operating activities, total indebtedness or any other measures of operating performance, liquidity or indebtedness derived in accordance with GAAP.
| AirSculpt Technologies, Inc. and Subsidiaries Selected Consolidated Financial Data (Dollars in thousands, except shares and per share amounts) | ||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||
| Revenue | $ | 44,012 | $ | 51,004 | $ | 83,383 | $ | 98,624 | ||||||
| Operating expenses: | ||||||||||||||
| Cost of service | 17,201 | 18,827 | 33,151 | 36,869 | ||||||||||
| Selling, general and administrative(1) | 22,671 | 34,274 | 44,439 | 50,030 | ||||||||||
| Depreciation and amortization | 3,246 | 2,885 | 6,488 | 5,690 | ||||||||||
| Loss/(gain) on disposal of long-lived assets | 108 | (1 | ) | 108 | 4 | |||||||||
| Total operating expenses | 43,226 | 55,985 | 84,186 | 92,593 | ||||||||||
| Income/(loss) from operations | 786 | (4,981 | ) | (803 | ) | 6,031 | ||||||||
| Interest expense, net | 1,562 | 1,515 | 3,187 | 3,047 | ||||||||||
| Pre-tax net (loss)/income | (776 | ) | (6,496 | ) | (3,990 | ) | 2,984 | |||||||
| Income tax (benefit)/expense | (185 | ) | (3,290 | ) | (552 | ) | 161 | |||||||
| Net (loss)/income | $ | (591 | ) | $ | (3,206 | ) | $ | (3,438 | ) | $ | 2,823 | |||
| (Loss)/income per share of common stock | ||||||||||||||
| Basic | $ | (0.01 | ) | $ | (0.06 | ) | $ | (0.06 | ) | $ | 0.05 | |||
| Diluted | $ | (0.01 | ) | $ | (0.06 | ) | $ | (0.06 | ) | $ | 0.05 | |||
| Weighted average shares outstanding | ||||||||||||||
| Basic | 59,590,033 | 57,557,178 | 59,066,400 | 57,489,466 | ||||||||||
| Diluted | 59,590,033 | 57,557,178 | 59,066,400 | 58,066,133 | ||||||||||
| (1) | During the first quarter of fiscal year 2024, the Company recorded a cumulative reversal of stock compensation expense of |
| AirSculpt Technologies, Inc. and Subsidiaries Selected Financial and Operating Data (Dollars in thousands, except per case amounts) | |||||
| June 30, 2025 | December 31, 2024 | ||||
| Balance Sheet Data (at period end): | |||||
| Cash and cash equivalents | $ | 8,189 | $ | 8,235 | |
| Total current assets | 16,405 | 17,117 | |||
| Total assets | $ | 198,367 | $ | 209,996 | |
| Current portion of long-term debt | $ | 4,550 | $ | 4,250 | |
| Deferred revenue and patient deposits | 1,121 | 1,169 | |||
| Total current liabilities | 25,829 | 28,609 | |||
| Long-term debt, net | 53,188 | 65,456 | |||
| Revolving credit funds payable | — | 5,000 | |||
| Total liabilities | $ | 107,210 | $ | 130,706 | |
| Total stockholders’ equity | $ | 91,157 | $ | 79,290 | |
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Cash Flow Data: | |||||||||||||||
| Net cash provided by (used in): | |||||||||||||||
| Operating activities | $ | 4,984 | $ | 3,442 | $ | 5,852 | $ | 6,807 | |||||||
| Investing activities | (265 | ) | (4,018 | ) | (2,166 | ) | (5,580 | ) | |||||||
| Financing activities | (2,083 | ) | (527 | ) | (3,732 | ) | (1,623 | ) | |||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Other Data: | |||||||||||||||
| Number of facilities | 32 | 27 | 32 | 27 | |||||||||||
| Number of total procedure rooms | 67 | 57 | 67 | 57 | |||||||||||
| Cases | 3,392 | 3,949 | 6,468 | 7,695 | |||||||||||
| Revenue per case | $ | 12,975 | $ | 12,916 | $ | 12,892 | $ | 12,817 | |||||||
| Adjusted EBITDA (1) | $ | 5,835 | $ | 6,868 | $ | 9,590 | $ | 14,205 | |||||||
| Adjusted EBITDA margin (2) | |||||||||||||||
| (1) A reconciliation of this non-GAAP financial measure appears below. |
| (2) Defined as Adjusted EBITDA as a percentage of revenue. |
| AirSculpt Technologies, Inc. and Subsidiaries Supplemental Information (Dollars in thousands, except per case amounts) | |||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||
| Same-center Information (1): | |||||||||||
| Cases | 3,079 | 3,949 | 5,916 | 7,695 | |||||||
| Case growth | (22.0)% | N/A | (23.1)% | N/A | |||||||
| Revenue per case | $ | 12,911 | $ | 12,916 | $ | 12,846 | $ | 12,817 | |||
| Revenue per case growth | —% | N/A | N/A | ||||||||
| Number of facilities | 27 | 27 | 27 | 27 | |||||||
| Number of total procedure rooms | 57 | 57 | 57 | 57 | |||||||
| (1) | For the three months ended June 30, 2025 and 2024, we define same-center case and revenue growth as the growth in each of our cases and revenue at facilities that were owned and operated during the three months ended June 30, 2025 and 2024, respectively. At facilities that were not owned or operated for the entirety of the prior year period, the current year period has been pro-rated to reflect only growth experienced during the portion of the three months ended June 30, 2025 in which such facilities were owned and operated during the three months ended June 30, 2024. We define same-center facilities and procedure rooms based on if a facility was owned or operated as of June 30, 2024. |
| For the six months ended June 30, 2025 and 2024, we define same-center case and revenue growth as the growth in each of our cases and revenue at facilities that were owned and operated during the six months ended June 30, 2025 and 2024, respectively. At facilities that were not owned or operated for the entirety of the prior year period, the current year period has been pro-rated to reflect only growth experienced during the portion of the six months ended June 30, 2025 in which such facilities were owned and operated during the six months ended June 30, 2024. We define same-center facilities and procedure rooms based on if a facility was owned or operated as of June 30, 2024. | |
| AirSculpt Technologies, Inc. and Subsidiaries Reconciliation of Non-GAAP Financial Measures (Dollars in thousands) | |
We report our financial results in accordance with GAAP, however, management believes the evaluation of our ongoing operating results may be enhanced by a presentation of Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income and Adjusted Net Income per Share, which are non-GAAP financial measures.
We define Adjusted EBITDA as net (loss)/income excluding depreciation and amortization, net interest expense, income tax (benefit)/expense, restructuring and related severance costs, loss/(gain) on disposal of long-lived assets, and equity-based compensation.
We define Adjusted Net Income as net (loss)/income excluding restructuring and related severance costs, loss/(gain) on disposal of long-lived assets, equity-based compensation and the tax effect of these adjustments.
We include Adjusted EBITDA and Adjusted Net Income because they are important measures on which our management assesses and believes investors should assess our operating performance. We consider Adjusted EBITDA and Adjusted Net Income each to be an important measure because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis. Adjusted EBITDA has limitations as an analytical tool including: (i) Adjusted EBITDA does not include results from equity-based compensation and (ii) Adjusted EBITDA does not reflect interest expense on our debt or the cash requirements necessary to service interest or principal payments. Adjusted Net Income has limitations as an analytical tool because it does not include results from equity-based compensation.
We define Adjusted EBITDA Margin as Adjusted EBITDA as a percentage of revenue. We define Adjusted Net Income per Share as Adjusted Net Income divided by weighted average basic and diluted shares. We included Adjusted EBITDA Margin and Adjusted Net Income per Share because they are important measures on which our management assesses and believes investors should assess our operating performance. We consider Adjusted EBITDA Margin and Adjusted Net Income per Share to be important measures because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis.
The following table reconciles Adjusted EBITDA and Adjusted EBITDA Margin to net (loss)/income, the most directly comparable GAAP financial measure:
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Net (loss)/income | $ | (591 | ) | $ | (3,206 | ) | $ | (3,438 | ) | $ | 2,823 | ||||
| Plus | | ||||||||||||||
| Equity-based compensation(1) | 1,352 | 4,873 | 2,591 | (1,908 | ) | ||||||||||
| Restructuring and related severance costs | 343 | 4,092 | 1,206 | 4,388 | |||||||||||
| Depreciation and amortization | 3,246 | 2,885 | 6,488 | 5,690 | |||||||||||
| Loss/(gain) on disposal of long-lived assets | 108 | (1 | ) | 108 | 4 | ||||||||||
| Interest expense, net | 1,562 | 1,515 | 3,187 | 3,047 | |||||||||||
| Income tax (benefit)/expense | (185 | ) | (3,290 | ) | (552 | ) | 161 | ||||||||
| Adjusted EBITDA | $ | 5,835 | $ | 6,868 | $ | 9,590 | $ | 14,205 | |||||||
| Adjusted EBITDA Margin | 13.3 | % | 13.5 | % | 11.5 | % | 14.4 | % | |||||||
| (1) | During the first quarter of fiscal year 2024, the Company recorded a cumulative reversal of stock compensation expense of |
| AirSculpt Technologies, Inc. and Subsidiaries Reconciliation of Non-GAAP Financial Measures (Dollars in thousands) | |||||||||||||||
| The following table reconciles Adjusted Net Income and Adjusted Net Income per Share to net income/(loss), the most directly comparable GAAP financial measure: | |||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Net (loss)/income | $ | (591 | ) | $ | (3,206 | ) | $ | (3,438 | ) | $ | 2,823 | ||||
| Plus | |||||||||||||||
| Equity-based compensation(1) | 1,352 | 4,873 | 2,591 | (1,908 | ) | ||||||||||
| Restructuring and related severance costs | 343 | 4,092 | 1,206 | 4,388 | |||||||||||
| Loss/(gain) on disposal of long-lived assets | 108 | (1 | ) | 108 | 4 | ||||||||||
| Tax effect of adjustments | (25 | ) | (618 | ) | (388 | ) | 1,713 | ||||||||
| Adjusted net income | $ | 1,187 | $ | 5,140 | $ | 79 | $ | 7,020 | |||||||
| Adjusted net income per share of common stock (2) | |||||||||||||||
| Basic | $ | 0.02 | $ | 0.09 | $ | — | $ | 0.12 | |||||||
| Diluted | $ | 0.02 | $ | 0.09 | $ | — | $ | 0.12 | |||||||
| Weighted average shares outstanding | |||||||||||||||
| Basic | 59,590,033 | 57,557,178 | 59,066,400 | 57,489,466 | |||||||||||
| Diluted | 60,379,884 | 57,990,621 | 59,802,603 | 58,066,133 | |||||||||||
| (1) | During the first quarter of fiscal year 2024, the Company recorded a cumulative reversal of stock compensation expense of |
| (2) | Diluted Adjusted Net Income Per Share is computed by dividing adjusted net income by the weighted-average number of shares of common stock outstanding adjusted for the dilutive effect of all potential shares of common stock. |
Investor Contact
Allison Malkin
ICR, Inc.
airsculpt@icrinc.com
FAQ
What were AirSculpt's (AIRS) Q2 2025 earnings results?
How much debt did AirSculpt (AIRS) reduce in Q2 2025?
What is AirSculpt's (AIRS) revenue guidance for 2025?
What new services is AirSculpt (AIRS) launching?
Who is replacing Dennis Dean as AirSculpt's CFO?
